Cormorant Asset Management’s enGene Therapeutics ENGN Stock Holding History

Cormorant Asset Management’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,000,000	Closed	-$36.1M	–	48
2025 Q4	$36.1M	Buy	4,000,000 +1,676,405	+72%	+$13.4M	2.05%	15
2025 Q3	$15.9M	Hold	2,323,595	–	–	1.1%	23
2025 Q2	$8.46M	Hold	2,323,595	–	–	0.63%	30
2025 Q1	$10.4M	Hold	2,323,595	–	–	0.79%	29
2024 Q4	$15.5M	Buy	2,323,595 +1,323,595	+132%	+$10.3M	0.85%	30
2024 Q3	$6.6M	Hold	1,000,000	–	–	0.35%	38
2024 Q2	$9.43M	Hold	1,000,000	–	–	0.55%	36
2024 Q1	$16.9M	Buy	+1,000,000	New	+$12.2M	0.75%	36

Other funds holding ENGN

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Blue Owl Capital Holdings New York $369M AUM 78.25% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $4.85B AUM 144% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return